Management of Cervical Ectopic Pregnancies: A Scoping Review
- PMID: 34259461
- DOI: 10.1097/AOG.0000000000004423
Management of Cervical Ectopic Pregnancies: A Scoping Review
Abstract
Objective: To investigate published cases of cervical ectopic pregnancy between 2000 and 2018 and compare management strategies and treatment success rates based on initial patient characteristics.
Methods: PubMed, EMBASE, and Web of Science were searched to capture peer-reviewed citations published between 2000 and 2018. Cases reporting either β-hCG level, crown-rump length, or gestational sac diameter for each individual patient were included. Data regarding the article information, patient characteristics, treatment used, and outcomes were collected. Initial success was defined as resolution of the cervical ectopic pregnancy with the predefined treatment plan. Initial failure was defined as the requirement of additional unplanned interventions due to the predefined treatment plan not being successful. End success was defined as resolution of the cervical ectopic pregnancy without hysterectomy.
Results: A total of 204 articles from 44 countries comprising 454 cases were reviewed. The initial β-hCG level ranged from 9 to 286,500, with a median of 14,773, and gestational age ranged from 4 to 18 weeks, with an average of 7 4/7 weeks (±2 0/7 weeks). In looking at initial success, compared with methotrexate alone, dilation, and curettage (odds ratio [OR] 2.26; 95% CI 2.64-10.45), dilation and curettage combined with uterine artery embolization (OR 4.85; 95% CI 2.06-11.44) and uterine artery embolization (OR 5.17; 95% CI 1.14-23.53) were more effective options. More than half of patients (50.2%) required multiple interventions, and 41 (9%) resulted in hysterectomy.
Conclusions: Management of cervical ectopic pregnancies should be guided by patient stability, β-hCG level, size of pregnancy, and fetal cardiac activity but may benefit from a planned multimodal approach.
Copyright © 2021 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Financial Disclosure Katharine White reports that money was paid to her institution by Bayer and Merck. She received funds from Fitbit Inc. and Mithra Pharmaceuticals (grant support to the institution). The other authors did not report any potential conflicts of interest.
References
-
- Celik C, Bala A, Acar A, Gezginç K, Akyürek C. Methotrexate for cervical pregnancy. A case report. J Reprod Med 2003;48:130–2.
-
- Samal SK, Rathod S. Cervical ectopic pregnancy. J Nat Sci Biol Med 2015;6:257–60. doi: 10.4103/0976-9668.149221 - DOI
-
- Sharma A, Ojha R, Mondal S, Chattopadhyay S, Sengupta P. Cervical intramural pregnancy: report of a rare case. Niger Med J 2013;54:271–3. doi: 10.4103/0300-1652.119670 - DOI
-
- Hosni MM, Herath RP, Mumtaz R. Diagnostic and therapeutic dilemmas of cervical ectopic pregnancy. Obstet Gynecol Surv 2014;69:261–76. doi: 10.1097/OGX.0000000000000062 - DOI
-
- Takeda K, Mackay J, Watts S. Successful management of cervical ectopic pregnancy with bilateral uterine artery embolization and methotrexate. Case Rep Emerg Med 2018 May 3. doi: 10.1155/2018/9593824 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
